. The regulatory subunit was substituted with the 21 kDa DVI ( Supplementary Fig. 1b ) 10 . The 72 kDa calpastatin inhibits heterodimeric calpains with nanomolar affinity, being composed of a non-inhibitory 12 kDa leader L domain and four 15-kDa calpain inhibitory repeats ( Supplementary Fig. 1b ) 6 . Each repeat contains three regions (A-C) predicted to interact with calpain 6 . We optimized the calpain-calpastatin complex by truncating calpastatin from a longer construct (residues 119-238) on the basis of results from limited proteolysis and NMR spectroscopy, both of which identified the amino-and carboxy-terminal mobile regions that impeded crystallization ( Fig. 1b and Supplementary Fig. 2 ).
Calpastatin recognizes the Ca 21 -induced conformation of m-calpain but does not coordinate Ca 21 in the complex (Fig. 1a) . Regions A and C fold as amphipathic helices when bound to the Ca 21 induced hydrophobic pockets in the corresponding penta-EF-hand domains ( Supplementary Fig. 3 ). Previously, homology modelling based on the Ca 21 -dependent complex between DVI and region C of calpastatin predicted the mode of binding for region A 11 . Regions A and B of calpastatin engage sites in DIV and DI-III, respectively. Region B associates with DI-III to obstruct the active site in the extended substrate-like orientation. Intrinsic disorder in the free state enables calpastatin to adapt structurally on binding to the substrate-binding cleft of calpain, distantly resembling the inhibitory conformation of the broad-specificity, structured protease inhibitors, the cystatins 12 ( Supplementary Fig. 4 ). Region B is anchored on either side of the active site C105S and avoids proteolysis by forcing a kink (Gly 174-Ile-Lys-Glu-Gly 178) between the flanking residues-Leu 173 at the substrate binding S2 subsite and Thr 179 at S19 (Fig. 2a, b) . The unprimed and primed substrate binding subsites are N-and C-terminal, respectively, from the scissile bond P1-P19. S and P distinguish protein and substrate subsites, respectively. N-terminal to the kink, residues Val 161-Leu 170 participate in hydrogen bonds mediated by backbone atoms (Supplementary Table 2 ) and hydrophobic interactions with the DIII surface that juxtaposes the active site (Fig. 2b) . The remainder of region B binds to the DI-II (Fig. 2a) . Ala 172 marks the S3 site whereas the Leu 173 interaction is of particular importance at the S2 pocket, the main specificity determinant of calpains 13, 14 . The side chain of Leu 173 at S2 is superimposable to Leu 2 of leupeptin in complex with the protease core DI-II of m-calpain, mI-II (ref. 15; Supplementary Fig. 5 ). C-terminal to the kink, region B engages the S19-S29-S39 subsites with residues Thr 179-Ile-Pro 181. The conformation of Pro 181-Pro-Glu-Tyr 184 changes the direction as the Glu 183-Lys 190 helix targets DI.
We tested the mechanism of inhibition by shortening the kink through deletion of Lys 176, Glu 177 or both. In all instances, the low nanomolar half-maximal inhibitory concentration (IC 50 ) values for m-calpain inhibition, derived from initial rate analysis, did not change significantly compared to wild type ( Supplementary Fig. 6a ). However, all mutants succumbed to proteolysis within the kink, permitting catalytic cleft access and resulting in complete autoproteolysis of the complex within hours (Fig. 2c) . The 5-residue kink is therefore essential to overcome proteolysis and its length has indeed been conserved ( Supplementary Fig. 2b) 6 . An 18-residue peptide B1, specific for DI-II (Ala 172-Glu 189), inhibited m-calpain with an IC 50 of 410 6 80 nM (mean 6 s.e.m., Supplementary Fig.  6b ). Others have shown that a 27-residue peptide, corresponding to Asp 163-Glu 189 of region B, inhibited m-calpain with an IC 50 of ,30 nM 16 . Residues Leu 173-Gly 174 and Thr 179-Ile-Pro 181 corresponding to the substrate subsites P2-distorted P1 and P19-P29-P39, respectively, were identified as 'hotspots' that impaired inhibition when replaced with Ala (ref. 17) . Replacing the intact 27-residue peptide with the corresponding N-and C-terminal peptidesAsp 163-Gly 174 and Lys 175-Ala 189 (human sequence)-abolished calpain inhibition 17 . Taken together, these data suggest that DIII anchoring by region B enhances inhibitory activity .10-fold and support the structure-based occluding-loop mechanism. The Ca 21 -dependent reversible interaction between calpastatin and calpain is biologically relevant and, in light of the length of the occluding loop, it indicates that the wild-type inhibitor, unlike the shorter loop mutants, may recycle once dissociated from the protease. This overcomes the need for new synthesis of calpastatin to maintain inhibition under conditions of fluctuating Ca 21 levels. Only regions A, C and the DI-II-binding residues of B are conserved among calpastatins ( Supplementary Fig. 2b ). The divergent intervening sequences connecting regions A, B and C are devoid of electron density (red dots in Fig. 1a) . NMR analysis of the complex between 15 N-labelled calpastatin and unlabelled calpain ( Fig. 1b and Supplementary Fig. 2a ) corroborated that the intervening sequences of calpastatin are intrinsically disordered (Supplementary Fig. 2b ). Conversely, calpastatin regions A, B and C bind calpain, become ordered and tumble slowly in solution as part of the 111 kDa complex, and were undetectable by NMR. DIII contains hotspots for proteolysis in the free and Ca 21 -bound m-calpain 18 , and its extensive interaction with calpastatin in the complex supports its resistance to trypsin ( Supplementary Fig. 2c ). The modular organization of calpastatin induced on binding to calpain emphasizes the role of the interspersed, flexible/disordered segments in the foldingbinding transitions of the structured regions at distant sites in calpain. Similar disorder was confirmed by NMR for a complex between m-calpain and repeat 1 of calpastatin at 10 mM CaCl 2 (ref. 19). Calpastatin regions A and C interact with calpain whereas the intervening regions are disordered 19 . Notably, calpastatin region B corresponding to Lys 176-Leu 188, which in our complex targets mainly DI, also interacts with calpain. At this CaCl 2 level the protease core is not aligned for catalysis and, therefore, the N terminus of H-HSQC (heteronuclear single quantum correlation) spectrum of the complex between 13 C, 15 N-labelled calpastatin (residues 128-226, Supplementary Fig. 2b ) and unlabelled calpain identified flexible/disordered residues of calpastatin. Connected sample strips from the HNCA NMR experiment are inset. Unprocessed calpain subunits and calpastatin are identified (arrows). Autolysis is blocked by wild-type calpastatin above I:E of 2. The K176D mutant fails to inhibit autolysis even at higher I:E, being digested in the loop to produce Coomassie-stained fragments (asterisks).
Fragmentation of the catalytic subunit is complete after ,1 h. . Local calpastatin-induced conformational changes in calpain are predicted for the gating loops of the protease core, found in alternative conformations in the structure of mI-II free or bound to inhibitors (Supplementary Figs 5 and 7) 7,15 . The calpain-calpastatin structure offers an unprecedented opportunity to study the Ca 21 -bound conformation of m-calpain (Fig. 3a) . The structures of inactive calpain 9, [20] [21] [22] , the Ca 21 -bound protease core 7, 23, 24 and Ca
21
-bound and free DVI (refs 25, 26) have generated valuable, incomplete models for calpain activation 8 . The calpaincalpastatin structure (Fig. 1a) represents the Ca 21 -activated conformation of m-calpain revealed by the realignment for catalysis of the protease core DI-II by two Ca 21 atoms, as described for mI-II (ref. 7; Supplementary Fig. 7 and Supplementary Table 3 ). DI-II is intimately associated with DIII, which undergoes conformational changes to interact specifically with DI, serving to stabilize the protease core and to maximize its catalytic activity. The EF-hand DIV and DVI bind four Ca 21 atoms each 27 , mediate the heterodimer interface by pairing of EF-hand 5 as in the apo-calpain 9 and show small changes between the Ca 21 -bound and free conformation (Supplementary Fig. 8 20 by overlapping DIII, which provides a central scaffold for the (re)arrangements of the vicinal domains through protein-protein interactions (Fig. 3a) . On binding Ca 21 , the upper DI-II lobe moves dorsal to frontal with respect to DIII, whereas the lower DIV-DVI lobe moves in the opposite direction. The tension on either side of the protease core, postulated in light of the Ca 21 -free m-calpain structure 9 and confirmed extensively biochemically 8 , is overcome by Ca 21 binding (Fig. 3a) . The discovery of the active conformation of the DI-III ensemble is significant as it identifies the missing conserved features at the extensive DI-II-DIII interface (Fig. 3b) .
We extrapolated the importance of this interface from structural analysis of the isolated protease core DI-II of m-calpain, mI-II. Owing to intrinsic instability of residues Gly 197-Gly 210 in DI, the unprimed side of the active site in mI-II collapses diminishing activity .1,000-fold compared to full-length m-calpain 24 . In the Ca 21 -bound heterodimer, residues 197-210 are stabilized, through salt bridges and hydrogen bonds, by conserved basic residues in DIII ( Fig. 3b and Supplementary Fig. 10 ). In particular, Arg 417 and Arg 420 from the basic loop, which adopts a different conformation in Ca 21 -free calpain ( Supplementary Fig. 9 ), and Arg 469 and Arg 500 from the b-sandwich core of DIII may provide critical support for the labile active site (Fig. 3b) .
In limb-girdle muscular dystrophy (LGMD)-2A patients, p94 (calpain 3) point mutants in DIII result in the typical atrophic phenotypes associated with impaired p94 activity in limb-girdle and trunk muscles 5 . The positions 490, 493, 541 and 572 in p94, corresponding to the conserved Arg residues (417, 420, 469 and 500, respectively) in DIII of m-calpain, are mutated to Trp, Gln or Pro in both familial and sporadic forms of the disease (http://www.dmd.nl) 28 . We probed the DI-II-DIII active interface by mutagenesis in m-calpain ( Fig. 3c and Supplementary Fig. 11 ). The R417A and R420A substitutions decreased m-calpain activity to one-half and one-quarter, respectively, and doubled the Ca 21 requirement in the latter. The R469A decreased activity .60-fold and doubled the Ca 21 requirement. Conservative Lys substitutions at 417, 420 or 469 did not rescue the phenotypes of Ala mutations ( Supplementary Fig. 11 ), collectively underscoring the importance of this interface for sustaining maximal calpain activity and providing an explanation for the effect of disease-causing p94 substitutions in LGMD-2A patients. 20 were aligned structurally based on DIII. The Ca 21 -bound DI-II is freed from inactivating tension at the interfaces between the anchor and DVI (T1), the acidic loop of DIII and the basic helix of DII (T2), and the basic loop of DIII and DVI (T3) 9, 21 . In Ca 21 bound calpain, the DIII-DIV linker is relaxed by shedding region 505-513 from the DIII core. DIII is Ca 21 -free and contacts DI-II and DIV (pink areas) extensively, but not DVI. The basic region in DIII stabilizes the labile active site (AS), and the DII-DIII linker contacts the basic helix in DII. Numbering of helices and strands is according to Supplementary Fig. 10 . Calpastatin inhibits m-and m-calpains 6 , which share the 28 kDa regulatory subunit predicted in both to bind calpastatin region C similarly ( Supplementary Figs 3b and 12) . Modelling of the complex between m-calpain and calpastatin illustrated that calpastatin regions A and B bind conserved pockets of the 80 kDa catalytic subunit and probably produce a similar set of inhibitory interactions with m-calpain ( Supplementary Fig. 12 ). We reported that mI-II is not inhibited by calpastatin repeat 1 (ref. Supplementary Fig. 6b,  c) . In contrast, repeat 1 and fragments AB and BC exhibited low nanomolar IC 50 values towards m-calpain ( Supplementary Fig.  6d ). Our results confirm the specificity of calpastatin for the heterodimeric m-and m-calpains and suggest that calpains that lack the small subunit, DIV and/or DIII may not support the same set of inhibitory interactions with calpastatin 8 . The calpain and calpastatin proteins represent a major ubiquitous cellular proteolytic system, the imbalance of which has been implicated in necrosis associated with stroke and neuronal injury and perhaps Alzheimer's disease, heart disease, cataract formation, type 2 diabetes, cancer and LGMD-2A 29 . Our study shows the mechanisms of activation by Ca 21 and inhibition by calpastatin of m-and m-calpains (Fig. 4) . Additional mechanisms of regulation for the calpain-calpastatin system include phosphorylation, membrane targeting and differential localization (Supplementary Fig. 13 ). The details of calpastatin specificity for the heterodimers may aid the design of new therapeutic agents.
METHODS SUMMARY
Repeat 1 of calpastatin and the m-calpain heterodimer, composed of an intact catalytic subunit and lacking the Gly-rich DV of the regulatory subunit, were expressed in Escherichia coli separately and were purified to homogeneity by fastperformance liquid chromatography (FPLC). Excess radio-labelled (for NMR) or unlabelled inhibitor was mixed with the protease in the presence of Ca 21 followed by further FPLC purification of the complex. The complex was subjected to limited proteolysis, NMR spectroscopy analysis, crystallization and X-ray crystallography structure determination. On the basis of the NMR assignments a shorter calpastatin fragment was generated and only its complex to m-calpain produced crystals. X-ray diffraction data collection was performed at three different US synchrotrons to improve the resolution. The crystal structure was obtained by molecular replacement using domains from previously determined calpain structures as search models. The active conformation of calpain and the mechanism of inhibition by calpastatin were probed by site-directed mutagenesis using standard calpain activity and calpastatin inhibition assays on the basis of calpain autolysis and hydrolysis of fluorogenic substrates. Truncated calpastatin constructs and synthetic peptides were tested for inhibitory specificity against full-length and truncated calpain.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
